首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1425167

電池超冷儲存市場－2024年至2029年預測

Cell Cryopreservation Market - Forecasts from 2024 to 2029

出版日期: 2024年01月30日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計細胞低溫儲存市場在預測期內將以 22.35% 的複合年成長率成長。

冷凍保存是一種透過將細胞、組織和其他生物結構暴露在極低的溫度下來來保存它們的技術。冷凍保存的應用包括細胞和器官保存、冷凍手術、生物化學和分子生物學中的應用、對食品科學的貢獻、生態學和植物生理學的相關性、輸血、骨髓移植、人工授精和體外受精（它涵蓋了多種領域）領域，包括眾多醫療應用，例如 IVF）。

冷凍保存對於儲存用於器官移植的人類白血球抗原分型的細胞、促進不同醫療中心之間細胞和組織的安全運輸以及研究未知傳染病和病原體非常有價值。它具有多種優勢，包括作為自然資源的作用。特別是，胚胎冷凍保存用於不孕症治療的首次應用是在 20 世紀 90 年代末，當時一名被診斷患有乳癌的女性在接受化療之前接受了自然體外受精。

市場促進因素

透過策略夥伴關係和聯盟崛起

在全球範圍內，戰略合作夥伴關係和聯盟在細胞冷凍保存市場的成長和開拓中發揮著至關重要的作用。這些聯盟使公司能夠利用互補的優勢和資源，促進互惠互利，並提供在競爭形勢中實現通用目標的策略路徑。例如，2022 年 1 月，生命科學產業溫控供應鏈解決方案的全球領導者 Cryoport, Inc. 宣布與 Cell Matters, SA 建立策略合作夥伴關係。此合作關係旨在為白血球衍生療法提供端到端冷凍保存服務，並支持自體和同種異體細胞療法。該合作夥伴關係還包括共同開拓銷售這些服務的商業性方法。與 Cell Matters 的這種策略關係不僅加強了 Cryoport Systems 的諮詢服務，而且有助於持續創新和開發適合市場需求的溫控包裝解決方案。這些合作夥伴關係和有針對性的收購符合生命科學產業不斷變化的需求，並加強了 Cryoport 的全面供應鏈解決方案。

此外，2023 年 6 月，專門從事細胞療法和病毒載體的全方位服務受託製造廠商(CDMO) SCTbio 將加入專門從事細胞療法和再生醫學先進解決方案的公司 Cyto-care。與.eu GmbH 合作。該合作夥伴關係的重點是提高歐洲細胞療法開發的冷凍保存品質。其目的是滿足白血球材料高效採集、冷凍保存、品管和物流能力的關鍵需求，以支持細胞治療工作流程的各個方面。此次合作強調了該行業對推進冷凍保存技術並將細胞治療無縫整合到醫療保健中的承諾。

推動該領域的新科學發展

在快速發展的細胞冷凍保存領域，持續的科學發展正在越來越頻繁地改變這一現狀。冷凍保存的潛在應用是巨大的，並且不斷擴大。目前該領域的研究特別關注整個器官的長期保存和持續活力，代表了醫學進步的重要前沿。目前，心臟、肝臟和胰臟等器官只能在體外存活數小時。冷凍保存有可能將這一關鍵時限顯著延長幾天甚至更長。這些突破性技術有可能徹底改變器官移植手術、減少物流挑戰並挽救更多生命。

這些進步的一個主要方面是新型冷凍保護劑的開發。它是保護細胞在冷凍和解凍過程中免受損傷的重要物質。另一個重要的發展是玻璃化，這是一種快速冷凍細胞的技術，使它們處於玻璃狀狀態而不是形成結晶。這種創新方法可望減少凍融過程中的細胞損傷。認知到解凍細胞與冷凍一樣有害，人們正在開發新的解凍方法。

總之，細胞冷凍保存的動態形勢是一項科學突破，它釋放了器官保存的新可能性，提高了冷凍保護劑的有效性，改進了方法，完善了細胞解凍的微妙過程，其特點是不斷發展。總的來說，這些進步有助於冷凍保存技術的持續發展，對醫學和醫療保健實踐產生深遠的影響。

市場挑戰

與應用相關的高成本

由於冷凍保護劑、儲存設施和專用設備的相關成本，細胞冷凍保存，特別是大規模應用，帶來了巨大的財務挑戰。採購關鍵冷凍保護劑對於在冷凍過程中保護細胞至關重要，其成本構成了整體支出。具有受控環境的先進儲存設施進一步推高了成本。

精確冷凍和解凍過程所需的專用設備也是細胞冷凍保存的財務考量。為了應對這些挑戰，人工智慧 (AI) 的整合正在成為一種變革性的解決方案。人工智慧的好處包括增強安全措施和最佳化生物材料的儲存條件，為低溫保存實踐提供具有成本效益的改進潛力。

依應用，細胞冷凍保存市場分為幹細胞、卵母細胞及胚胎卵子、精子細胞、肝細胞等。

細胞低溫儲存市場策略性地細分為特定應用。幹細胞（細胞凍存）可用於再生醫學，卵子和胚胎細胞儲存可用於輔助生殖技術，精子細胞凍存可用於不孕症治療，肝細胞儲存可用於促進藥物研究。「其他」類別強調了低溫保存的多種用途。總而言之，這些部分強調了低溫保存對再生醫學、生殖醫學和科學研究的不同貢獻。

歐洲預計將佔據細胞冷凍保存市場的巨大佔有率

預計歐洲將在細胞冷凍保存市場中發揮關鍵作用，該地區受到現代社會冷凍保存實踐探索的影響。這項探索由 CRYOSOCIETIES主導，計劃旨在探索冷凍對生命的時間性和基本概念的變革性影響。「CRYOSOCIETIES」由四個計劃組成，每個子項目都有助於透過人種學研究和理論框架全面了解「懸浮生命」的創造。第一個子計劃重點在於德國的臍帶血儲存。第二個子計劃將調查西班牙的卵子冷凍情況，探討女性決定儲存卵子的動機以及卵子冷凍保存在生殖診所和更廣泛的生殖部門中的作用。第三個子計劃重點關注英國瀕危和滅絕物種的低溫保存，特別是冰凍方舟慈善機構和 CryoArks 生物庫的工作。

為了補充這些實證研究，第四個子計劃採用理論方法並檢驗「暫停生命」的意義。這項理論探討旨在闡明與不同人體冷凍實踐相關的時間和空間機制。總之，「CRYOSOCIETIES」計劃對歐洲背景下的低溫保存進行了多方面的檢驗，並強調了其多樣化的應用，從再生治療到未來的繁殖和瀕危物種保護工作。

企業產品

細胞低溫保存溶液 (Irvine Scientific) - FUJIFILM Irvine Scientific 的細胞低溫保存溶液是一種化學成分明確的無蛋白質配方，嚴格遵守 cGMP 標準。 PRIME-XV FreezIS 冷凍保存產品有利於多種細胞類型的冷凍保存，例如間質幹細胞(MSC) 和人類 T 細胞。冷凍保存後，進行徹底的驗證以評估細胞標記、活力和倍數擴增。 PRIME-XV FreezIS 冷凍保存解決方案採用溫和的冷凍過程，可有效最大程度地減少冷衝擊造成的潛在損害。
細胞冷凍介質和鹽基溶液 (Sartorius) - Sartorius 提供生物保存解決方案，包括使用細胞冷凍介質和鹽基溶液進行短期冷凍保存和長期冷凍保存。 NutriFreez® 細胞冷凍、NutriStor® 專為保存細胞而客製化，包括幹細胞、T 細胞和 PBMC 等脆弱類型。這些解決方案確保在生物保存過程中提供無動物成分 (ACF) 條件，這對於在無異源和 ACF 系統中培養細胞時保持同質性非常重要。 NutriFreez(R) 和 NutriStor(R) 已經證明了經過驗證的可靠性和堅定不移的一致性，即使在低溫儲存、冷凍和解凍等過程中也表現出卓越的性能和恢復率。
細胞株冷凍保存 (Sigma-Aldrich) - 達姆施塔特 Merck KGaA 專門從事細胞株冷凍保存並具有多種優勢。這些包括降低微生物污染的風險、降低與其他細胞株交叉污染的可能性，以及降低遺傳漂變和型態變化的風險。工作總是使用經過傳代編號的細胞進行。這種方法不僅提高了整體效率，還降低了成本，包括消耗品和員工時間。

Cryopreservation is a technique that involves preserving organelles, cells, tissues, or other biological structures by subjecting them to extremely low temperatures. The applications of cryopreservation span various areas, including- preserving cells or organs; cryosurgery; applications in biochemistry and molecular biology; contributions to food sciences; relevance in ecology and plant physiology; and numerous medical applications, such as blood transfusion, bone marrow transplantation, artificial insemination, and in vitro fertilization (IVF).

Cryopreservation offers several advantages, including the ability to bank cells for human leukocyte antigen typing for organ transplantation, facilitating the safe transport of cells and tissues across different medical centers, and serving as a valuable resource for research into unknown transmissible diseases or pathogens. Notably, the first instance of embryo cryopreservation for fertility preservation occurred in the late 1990s, involving the application of a natural IVF cycle before chemotherapy in a woman diagnosed with breast cancer.

Market Drivers

Rise due to strategic partnerships and collaborations

Globally, strategic partnerships and collaborations play a pivotal role in driving growth and development in the cell cryopreservation market. These alliances allow companies to capitalize on complementary strengths and resources, fostering mutual benefits and providing a strategic pathway for achieving shared objectives amid a competitive landscape. For instance, in January 2022, Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced a strategic partnership with Cell Matters, S.A. This collaboration aims to deliver end-to-end cryopreservation services for leukapheresis-derived therapies, supporting both autologous and allogeneic cell therapies. The partnership includes the joint development of a commercial approach for marketing these services. This strategic relationship with Cell Matters not only enhances Cryoport Systems' consulting services but also contributes to ongoing innovation and the development of temperature-controlled packaging solutions tailored to market needs. These alliances and targeted acquisitions are strengthening Cryoport's comprehensive supply chain solutions, aligning with the evolving needs of the life sciences industry.

Further in June 2023, SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors, collaborated with Cyto-care.eu GmbH, a company specializing in advanced solutions for cell therapy and regenerative medicine. The collaboration is focused on enhancing the quality of cryopreservation for cell therapy development in Europe. The goal is to address the critical need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials, supporting various aspects of the cell therapy workflow. This partnership underscores the industry's commitment to advancing cryopreservation techniques and ensuring the seamless integration of cell therapies into the healthcare landscape.

New Scientific developments driving the field

In the rapidly advancing field of cell cryopreservation, ongoing scientific developments are reshaping the landscape with increasing frequency. The potential applications of cryopreservation are vast and continually expanding. Current research in this realm is particularly focused on the preservation of whole organs for extended storage and sustained viability, presenting a significant frontier in medical advancement. As it stands, organs like the heart, liver, and pancreas can endure only a few hours outside the body. Cryopreservation holds the promise of substantially extending this critical timeframe to several days or even longer. Such breakthroughs could revolutionize organ transplantation procedures, mitigating logistical challenges and potentially saving more lives.

A key facet of these advancements lies in the development of new cryoprotectants-substances crucial for shielding cells from damage during the freezing and thawing process. Another pivotal development involves vitrification, a technique that freezes cells so rapidly that they assume a glass-like state rather than forming ice crystals. This innovative approach holds promise in reducing cell damage during freezing and thawing. Recognizing that thawing cells can be as detrimental as freezing them, novel thawing methods are also under development.

In essence, the dynamic landscape of cell cryopreservation is marked by the continuous development of scientific breakthroughs, unlocking new possibilities for organ preservation, improving cryoprotectant efficacy, enhancing methods, and refining the delicate process of thawing cells. These advancements collectively contribute to the ongoing evolution of cryopreservation technologies with profound implications for medical science and healthcare practices.

Market Challenges

High cost associated with the application

Cryopreserving cells, especially in large-scale applications, pose significant financial challenges due to expenses associated with cryoprotectants, storage facilities, and specialized equipment. The procurement costs of crucial cryoprotectants, essential for safeguarding cells during freezing, contribute to the overall expenditure. Advanced storage facilities with controlled environments add further to the costs.

Specialized equipment required for precise freezing and thawing processes also factors into the financial considerations of cell cryopreservation. To address these challenges, the integration of artificial intelligence (AI) emerges as a transformative solution. AI's benefits include enhancing safety measures and optimizing the storage conditions of biological materials, presenting a potential for cost-effective improvements in cryopreservation practices.

By application, the cell cryopreservation market is segmented into stem cells, oocytes and embryotic cells, sperm cells, hepatocytes, and others

The cell cryopreservation market is strategically segmented, into specific applications. Stem cell cryopreservation holds promise for regenerative medicine, oocytes, and embryotic cell preservation supports assisted reproductive technologies, sperm cell cryopreservation aids fertility preservation, and Hepatocyte preservation facilitates drug research. The "others" category underscores cryopreservation's versatile applications. Altogether, these segments highlight cryopreservation's diverse contributions to regenerative medicine, reproductive health, and scientific research.

Europe is anticipated to hold a significant share of the Cell Cryopreservation Market

Europe is anticipated to play a significant role in the cell cryopreservation market, with the region being influenced by an exploration of cryopreservation practices within contemporary societies. This exploration is led by "CRYOSOCIETIES", a project delving into the transformative impact of cryopreservation on temporalities and the fundamental concept of life. "CRYOSOCIETIES" is structured into four subprojects, each contributing to a comprehensive understanding of the creation of "suspended life" through ethnographic studies and theoretical frameworks. The first subproject focuses on the storage of cord blood in Germany. The second subproject investigates the freezing of oocytes in Spain, exploring the motivations behind women's decisions to preserve their eggs and the role of oocyte cryopreservation within reproductive clinics and the broader reproductive sector. The third subproject concentrates on the cryopreservation of endangered or extinct species in the UK, particularly the initiatives of the Frozen Ark charity and the CryoArks biobank.

Complementing these empirical studies, the fourth subproject takes a theoretical approach, examining the implications of "suspended life." This theoretical exploration seeks to unravel the temporal and spatial regimes associated with various cryopreservation practices. In essence, the "CRYOSOCIETIES" project offers a multifaceted examination of cryopreservation within European contexts, shedding light on its diverse applications-from regenerative therapies to reproductive futures and conservation efforts for endangered species.

Market Developments

May 2022- OrganaBio, LLC, inaugurated a cutting-edge laboratory facility in Irvine, California, marking an expansion of its presence and capabilities from the southeast to the west coast. This new establishment is poised to provide comprehensive support services to clinical trial sponsors and Contract Research Organizations (CROs). The services encompass patient sample processing, analytical testing, cryopreservation, and storage. Leveraging OrganaBio's advanced techniques in cell isolation, characterization, and cryopreservation, the Irvine facility will replicate its success in collecting and processing patients' samples. The facility will incorporate state-of-the-art storage systems to ensure optimal preservation and long-term storage of samples.
December 2021- AMSBIO inaugurated a new office in Alkmaar, Netherlands, with the establishment of AMSBIO Europe BV. This strategic move is geared towards providing European customers swift and convenient access to the company's extensive range of high-quality products and consumables. Recognizing the significance of the European market, AMSBIO has long been planning measures to ensure that EU researchers can seamlessly receive next-day delivery of products without customs delays, import tariffs, or the need for additional documentation. The newly established AMSBIO Europe BV office is designed to streamline operations and maintain local stock, allowing EU customers to order and receive the company's market-leading life science products efficiently and at reduced costs.
October 2022- FUJIFILM Irvine Scientific, Inc., a prominent global player in the realm of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, unveiled a noteworthy development. The company announced that its PRIME-XV Stem FreezIS DMSO-Free cryopreservation medium has been selected as an excipient for an FDA-authorized clinical trial led by Vitro Biopharma. In this clinical trial, spearheaded by Vitro Biopharma, the primary objective is to explore both the safety and efficacy of intravenous infusions of their stem cell therapy product. The utilization of FUJIFILM Irvine Scientific's cryopreservation medium in this trial underscores the critical role it plays in maintaining the integrity and viability of stem cells, contributing to the success of advanced therapies and their potential applications in medical treatments.

Company Products

Cell Cryopreservation Solutions (Irvine Scientific)- FUJIFILM Irvine Scientific's cell cryopreservation solutions are meticulously crafted as chemically defined and protein-free formulations, produced in strict adherence to cGMP standards. PRIME-XV FreezIS cryopreservation products facilitate the freezing of diverse cell types, such as human mesenchymal stem cells (MSCs) and human T cells. Following cryogenic preservation, thorough validation is conducted, assessing cell markers, viability, and fold expansion. The PRIME-XV FreezIS cryopreservation solutions employ a gradual freezing process, effectively minimizing potential damage arising from cold shock.
Cell Freezing Media and Salt-Based Solutions(Sartorius)- Sartorius presents biopreservation solutions encompassing both short-term cold storage and extended cryopreservation with its Cell Freezing Media and Salt-Based Solutions. Tailored for the preservation of cells, including delicate varieties like stem cells, T cells, and PBMCs, NutriFreez® cell freezing, and NutriStor®. These solutions ensure the provision of animal component-free (ACF) conditions during biopreservation, crucial for maintaining uniformity when cultivating cells in xeno-free and ACF systems. Demonstrating established reliability and steadfast consistency, NutriFreez® and NutriStor® exhibit a notable performance and recovery rate following processes such as cold storage, freezing, and thawing.
Cryopreservation Of Cell Lines (Sigma-Aldrich) - Merck KGaA, Darmstadt, specializes in the cryopreservation of cell lines, offering several advantages. These include a diminished risk of microbial contamination, a lowered likelihood of cross-contamination with other cell lines, and a reduced risk of genetic drift and morphological changes. The work is performed using cells at a consistently maintained passage number. This approach not only enhances overall efficiency but also contributes to reduced costs, encompassing consumables and staff time.

Market Segmentation

By Product

Cell Freezing Media
Equipment
Consumables

By Application

Stem Cells
Oocytes And Embryotic Cells
Sperm Cells
Hepatocytes
Others

By End Use

Biopharmaceutical & Pharmaceutical Companies
Research Institutes
Biobanks
Ivf Clinics
Others

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CELL CRYOPRESERVATION MARKET BY PRODUCT

5.1. Introduction
5.2. Cell Freezing Media
5.3. Equipment
5.4. Consumables

6. CELL CRYOPRESERVATION MARKET BY APPLICATION

6.1. Introduction
6.2. Stem Cells
6.3. Oocytes and Embryotic Cells
6.4. Sperm Cells
6.5. Hepatocytes
6.6. Others

7. CELL CRYOPRESERVATION MARKET BY END-USE

7.1. Introduction
7.2. Biopharmaceutical & Pharmaceutical Companies
7.3. Research Institutes
7.4. Biobanks
7.5. IVF Clinics
7.6. Others

8. CELL CRYOPRESERVATION MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others